Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check29 days agoChange DetectedThe webpage has been updated to include detailed information about a clinical trial for a new treatment involving amivantamab and lazertinib for metastatic non-small cell lung cancer (NSCLC), including study details, eligibility criteria, and contact information for participation.SummaryDifference100%
- Check36 days agoChange DetectedThe web page has undergone significant deletions, including the removal of a service alert regarding planned maintenance and various details about a clinical study involving amivantamab and lazertinib for non-small cell lung cancer. This includes the study's overview, eligibility criteria, and contact information.SummaryDifference90%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check50 days agoChange DetectedA service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours beginning at 9 PM EDT.SummaryDifference0.7%
Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.